SWX:GALDPharmaceuticals
Assessing Galderma Group (SWX:GALD) Valuation As New Neuromodulator Data Reinforces Relfydess And Dysport
Galderma Group (SWX:GALD) is back in focus after announcing fresh clinical and real world data for its neuromodulators Relfydess and Dysport at the TOXINS 2026 International Conference in Madrid.
See our latest analysis for Galderma Group.
The fresh neuromodulator data arrives after a softer near term patch for the stock, with a 30 day share price return of 5.53% and a 7 day share price return of a 3.21% decline, even though the 90 day share price return is 12.84% and the 1 year total...